Liquidia Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LQDA research report →
Range $54 – $130
Price Chart
About the company
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.
- CEO
- Roger A. Jeffs
- IPO
- 2018
- Employees
- 216
- HQ
- Morrisville, NC, US
Get TickerSpark's AI analysis on LQDA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $4.90B
- P/E
- -52.84
- Fwd P/E
- 14.03
- PEG
- 0.03
- P/S
- 7.89
- P/B
- -191.58
- EV/EBITDA
- -52.53
- Div Yield
- 0.00%
- Gross Margin
- 92.68%
- Op Margin
- -15.55%
- Net Margin
- -15.15%
- ROE
- -116.64%
- ROIC
- -55.68%
Latest fiscal year · YoY change
- Revenue
- $158.32M+1031.2%
- Gross Profit
- $145.08M+1687.3%
- Op Income
- $-51,376,000
- Net Income
- $-68,924,000+47.1%
- EPS
- $-0.80+51.8%
- OCF Growth
- +61.8%
- FCF Growth
- +59.3%
- 52W High
- $93.61
- 52W Low
- $22.31
- 50D MA
- $48.02
- 200D MA
- $54.95
- Beta
- 0.54
- RSI (14)
- 59
- Avg Volume
- 3.52M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Liquidia said YUTREPIA posted its fifth straight quarter of growth, with strong Q3 sales and EBITDA, and management argued the settlement removes the main legal overhang while the product’s launch momentum remains intact.· November 10, 2026
- Q3 net product sales grew 31% to $222.7 million; adjusted EBITDA was $140.5 million, the fifth consecutive quarterly increase.
- Gross margin was approximately 94%, while SG&A fell to 26% of revenue from 33% in Q2, showing operating leverage.
- Management said YUTREPIA has delivered 5 consecutive quarters of growth in prescriptions, revenue and adjusted EBITDA, despite litigation-related disruption.
- PAH is now the main growth driver: more than 60% of prescriptions since launch had a PAH diagnosis, rising to over 70% in September.
- Cash and cash equivalents ended Q3 at $396.1 million before settlement payments, and management said it has no need to raise extra capital.
Liquidia reported third-quarter 2026 net product sales of $222.7 million, up $52 million or 31% from last quarter. Of that, $212.2 million was paid patient demand sales. Gross margin was approximately 94%, R&D expense was $25.3 million, and SG&A was nearly flat sequentially but fell to 26% of revenue from 33% in Q2. The company reported a GAAP net loss of $236.3 million, reflecting a one-time settlement charge of $389.7 million, of which $380.7 million is payable in cash through April 2027. Adjusted EBITDA was $140.5 million. Cash and cash equivalents were $396.1 million prior to settlement payments, up $111.9 million from Q2. Management did not provide a formal next-quarter or full-year revenue guide, but said October shipments reached the highest level since launch, daily referrals in October were more than 75% of the Q3 daily rate, conversion rates remain above 87%, and it expects to provide more information on 2027 in early January.
Roger Jeffs struck an upbeat, combative tone, saying the settlement removes the litigation overhang and lets the company focus on growth. He repeatedly emphasized YUTREPIA’s differentiated profile, especially dosing flexibility, broad prescriber adoption, and the view that October represented a temporary pause rather than a trend. He also laid out a broad pipeline plan beyond PAH, including ongoing and planned studies in PH-ILD, PAH, Raynaud’s/systemic sclerosis, and PH-COPD.
Michael Kaseta highlighted strong operating performance and cash generation: $222.7 million in sales, gross margin around 94%, SG&A at 26% of revenue, and adjusted EBITDA of $140.5 million. He said cash and cash equivalents were $396.1 million before settlement payments, up $111.9 million sequentially, and stated the company has no need to raise extra capital and is not changing its operating plan. He also explained that the gap between $222.7 million total sales and $212.2 million paid demand sales was driven by normal stocking dynamics as demand grows, not by free-drug programs.
Analysts focused on the size of the PAH/PH-ILD patient opportunity, the impact of the settlement on prescribing and reauthorization, and the timeline for future guidance. Management said existing PH-ILD patients do not have to switch, formulary positions are unchanged, and reauthorizations are expected to proceed normally; it also said the attestation requirement is a standard checkbox on referral forms. On growth, management said October referrals were still above 75% of Q3 levels, October shipments were the highest since launch, and it expects to offer more explicit 2027 guidance in early January. Questions also covered the settlement offer from United, which management said would have given United 100% of PH-ILD revenue and 50% of non-infringing PAH revenue, which they called unreasonable.
The bull case from this call is that YUTREPIA is still growing quickly even through legal noise, with 31% quarterly sales growth, strong adjusted EBITDA, and gross margins near 94%. Management believes the settlement clears the path for continued adoption in PAH, where it sees substantial room to grow share because only about half of treated PAH patients are on a prostacyclin and its dosing flexibility is differentiated.
The key risks are the remaining cash settlement obligation of $380.7 million through April 2027 and the fact that management acknowledged some temporary referral volatility after the court ruling and settlement ambiguity. The company is also still in a launch phase, and management said it wants more data before giving 2027 guidance, so near-term revenue visibility is limited. In addition, the broader pipeline is still early and depends on future study readouts across multiple indications.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 72.4%
- Shares Outstanding
- 90.11M
- Float Shares
- 65.25M
of shares held by institutions
366 13F filers
Buy/sell ratio 0.64. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 11.26M | ▲ 473.35K |
| Farallon Capital Management, L.L.C. | 8.37M | ▼ 291.00K |
| Caligan Partners LP | 8.12M | 0 |
| Vanguard Group Inc | 4.01M | ▲ 52.67K |
| Findell Capital Management LLC | 3.50M | 0 |
| Vanguard Capital Management LLC | 3.24M | ▲ 98.71K |
| State Street Corp | 3.22M | ▲ 185.00K |
| Vanguard Portfolio Management LLC | 2.82M | ▲ 1.28M |
| Opaleye Management Inc. | 2.45M | ▼ 97.50K |
| Geode Capital Management, LLC | 2.17M | ▲ 53.49K |
| Bank Of America Corp | 1.99M | ▼ 296.23K |
| Price T Rowe Associates Inc | 1.94M | ▲ 987.21K |
Held by 361 ETFs
Biggest fund positions in LQDA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 16, 26 | Schundler Russell | other | 8,870 |
| Nov 16, 26 | KIRSCH ARTHUR S | other | 8,914 |
| Nov 16, 26 | KIRSCH ARTHUR S | other | 8,914 |
| Nov 16, 26 | Alterson Harold | other | 5,322 |
| Nov 16, 26 | Alterson Harold | other | 0 |
| Oct 26, 26 | Boyle Dana | sell | 1,581 |
| Oct 26, 26 | Adair Jason | sell | 688 |
| Oct 9, 26 | Schundler Russell | other | 6,409 |
| Oct 9, 26 | Schundler Russell | other | 3,758 |
| Oct 12, 26 | Schundler Russell | sell | 13,692 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our LQDA coverage
Recent articles, reports, and earnings notes.
Want a deeper read on LQDA?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Liquidia: Yutrepia's PAH Franchise Has Room To Grow
seekingalpha.com · Nov 14
LQDA Q3 Earnings Beat Estimates on Robust Yutrepia Sales
zacks.com · Nov 11
LQDA Q3 Earnings Call Highlights Growth and Post-Settlement Outlook
zacks.com · Nov 11
Liquidia (NASDAQ:LQDA) Stock Price Breaks Above Fifty Day Moving Average Following Weak Earnings
defenseworld.net · Nov 11
Liquidia Q3 Earnings Call Highlights
marketbeat.com · Nov 10
Liquidia Corporation (LQDA) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 10
Liquidia Corporation (LQDA) Q3 Earnings and Revenues Beat Estimates
zacks.com · Nov 10
Liquidia Corporation to Present at 2026 Jefferies Global Healthcare Conference
globenewswire.com · Nov 10
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
